daiichi sankyo co ltd (4568:Tokyo)
Transactions by DAIICHI SANKYO CO LTD (4568) in the last 6 months
Daiichi Sankyo Company, Limited (TSE:4568) signed an agreement to acquire Ambit Biosciences Corporation (NasdaqGM:AMBI) from Avalon Ventures, LLC and other shareholders for approximately $350 million in cash on September 28, 2014. Daiichi will launch a tender offer and pay $15 per share and issue one contingent value right, entitling the holder to receive an additional cash payment of up to $4.5 for each share if certain commercialization related milestones are achieved. ...
Apposite Capital LLP
Apposite Healthcare Fund
Avalon Ventures, LLC
Caduceus Private Investments III, L.P.
Foresite Capital Management, L.L.C.
Forward Ventures IV, L.P.
Great Point Partners, LLC
GrowthWorks Canadian Fund Ltd., L.P.
MedImmune Ventures, Inc.
New Leaf Venture Partners
OrbiMed Advisors, L.L.C.
OrbiMed Associates III, LP
Perseus-Soros Biopharmaceutical Fund, L.P.
Radius Ventures, LLC
Senrigan Capital Group Limited
Leerink Partners LLC
|Array BioPharma Inc||$4.75 USD||+0.11|
|BioCryst Pharmaceuticals Inc||$12.01 USD||+0.175|
|Infinity Pharmaceuticals Inc||$16.70 USD||+0.05|
|Ipsen SA||€43.00 EUR||+0.18|
|View Industry Companies|